Published in Hepatitis Weekly, June 20th, 2005
According to recent research from Italy, "the combination of lamivudine and hepatitis B immunoglobulin (HBIG) reduces the risk of hepatitis B virus (HBV) recurrence after liver transplantation (LT). However, the efficacy of this strategy and the need for combined therapy with adefovir dipivoxil (ADV) in patients who select lamivudine-resistant strains (YMDD) before surgery is still unknown."
"Twenty-two patients treated with lamivudine (LAM) who underwent LT after YMDD-mutant selection were studied," wrote A. Marzano and colleagues, Osped San Giovanni Battista...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly